Retrospective data reveals survival differences in advanced breast cancer treatments
NCT ID NCT06086340
Summary
This study looked back at existing medical records to compare how long patients lived after receiving two different treatments for advanced breast cancer. It included 779 Medicare patients aged 65 and older whose cancer had already spread when first diagnosed. Researchers analyzed whether adding the drug palbociclib to standard hormone therapy helped patients live longer compared to hormone therapy alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer New York
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.